Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Relay Therapeutics

Tracked across 2 events · 13 articles · First seen Apr 27, 2026 · Last active Sep 22, 2026

Sentiment
42
Attention
6
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 75
Tech
Impact: Relay Therapeutics is advancing its drug zovegalisib into Phase 3 development for metastatic breast cancer, which could significantly boost its market position and revenue if approved.
Apr 27, 2026 · 6 articles
2 10
Regulatory
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced on September 22, 2026 that the U.S. United States — Food and Drug Administration granted conditional acceptance of LYRFIGTU as the brand name for…
Impact: Relay Therapeutics is the licensor of lirafugratinib to Elevar Therapeutics for worldwide commercialization. Progress toward approval could yield milestone or royalty value for Relay, though it is a secondary beneficiary in this event.
Sep 22, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Relay Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.